Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies

Abstract

The proposed case definition permits data comparability among different medicinal products and among active as well as passive surveillance settings. It may form a basis for meaningful risk analysis and communication for regulators and healthcare professionals.